Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | GLB1 | P16278 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205387 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| SCHEMBL28341435 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| SCHEMBL6506788 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| SCHEMBL6506197 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| SCHEMBL60452 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| SCHEMBL20733674 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| Butane SCHEMBL2507294 | 0.97 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| Hydrochloric Acid SCHEMBL15141354 | 0.97 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| Water SCHEMBL28467820 | 0.97 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 | |
| Ammonia Solution, Strong SCHEMBL8765175 | 0.97 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023067560-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023053016-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3623361-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021067604-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | DREXEL UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020231808-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-3623361-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3083556-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-12-25 | — | — | EP | disclosed |
| CN-104558299-B | A kind of catalyst for being used to prepare low rule polypropylene | 中国石油化工股份有限公司 | 2018-01-23 | — | — | CN | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | HRH3 471/4885CYP1A2 3403/4885MAPK1 2284/4885 |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | HRH3 2354/4885CYP1A2 540/4885MAPK1 3038/4885 |
| US-20160311759-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | PHOSPHO1, SGMS1, ABCB4 | HRH3 684/4885CYP1A2 3352/4885MAPK1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.